ImmunityBio (NASDAQ:IBRX) Stock Price Up 1% – Time to Buy?

ImmunityBio, Inc. (NASDAQ:IBRX) shares were up 1% during trading on Friday . The company traded as high as $9.25 and last traded at $8.70. Approximately 45,076,080 shares changed hands during mid-day trading, an increase of 5% from the average daily volume of 42,903,035 shares. The stock had previously closed at $8.61.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. BTIG Research raised their price objective on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Jefferies Financial Group increased their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. HC Wainwright raised their price target on ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, January 26th. D. Boral Capital reiterated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research note on Tuesday, February 17th. Finally, Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.80.

ImmunityBio Price Performance

The stock has a market cap of $8.57 billion, a PE ratio of -21.22 and a beta of 0.16. The company has a 50 day moving average price of $4.48 and a two-hundred day moving average price of $3.12.

Insider Transactions at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 151,967 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the transaction, the director owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 226,967 shares of company stock valued at $1,531,912. 69.48% of the stock is owned by insiders.

Institutional Investors Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in ImmunityBio by 14.6% in the 4th quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock worth $362,000 after purchasing an additional 23,353 shares during the period. Corient Private Wealth LLC boosted its stake in shares of ImmunityBio by 69.7% in the 4th quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock worth $660,000 after buying an additional 136,858 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in shares of ImmunityBio in the fourth quarter worth $35,000. Empowered Funds LLC purchased a new stake in ImmunityBio during the fourth quarter valued at $28,000. Finally, VARCOV Co. purchased a new stake in ImmunityBio during the fourth quarter valued at $524,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.